R&D Department, Indena SpA, Viale Ortles 12, Milan, Italy.
Future Oncol. 2013 Nov;9(11):1717-25. doi: 10.2217/fon.13.165.
SAMITAL(®) (Indena SpA, Milan, Italy) is a new multicomponent and multiacting botanical formulation rationally designed for the relief of oral mucositis induced by chemotherapy and/or radiotherapy in oncological patients. Each of the individual botanical constituents of SAMITAL-standardized extracts of Vaccinium myrtillus, Macleaya cordata and Echinacea angustifolia have a long history of clinical use that corroborates their safety and activity in SAMITAL. A number of pilot trials in oncological patients demonstrated that SAMITAL has good clinical efficacy and tolerability as evidenced by its significant effects in terms of reduction of mucositis, pain and a general improvement in patient quality of life. Importantly, the use of this botanical formulation had the added benefit that patients were able to complete their chemotherapy/radiotherapy regimen. Phase II trials with SAMITAL as part of an overall clinical development program are currently ongoing in Italy and are planned in the USA.
SAMITAL（®）（意大利米兰的英诺珐公司）是一种新的多成分、多作用的植物配方，专门设计用于缓解肿瘤患者因化疗和/或放疗引起的口腔黏膜炎。SAMITAL 标准化提取物的每一种植物成分，包括越橘、博落回和狭叶松果菊，都有长期的临床应用历史，证明了它们在 SAMITAL 中的安全性和活性。一些在肿瘤患者中的初步试验表明，SAMITAL 具有良好的临床疗效和耐受性，其在减轻黏膜炎、疼痛和改善患者整体生活质量方面的显著效果就是证明。重要的是，这种植物配方的使用还有一个额外的好处，就是患者能够完成他们的化疗/放疗方案。SAMITAL 作为整体临床开发计划的一部分的 II 期试验目前正在意大利进行，并计划在美国进行。
